Drug Profile
AT 0701
Alternative Names: Anti influenza monoclonal antibody - Kling Biotherapeutics; AT0701Latest Information Update: 20 Dec 2023
Price :
$50
*
At a glance
- Originator AIMM Therapeutics
- Developer Kling Biotherapeutics; Undisclosed Company
- Class Antivirals; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Influenza virus infections
Most Recent Events
- 25 Sep 2020 No development reported - Phase-II for Influenza virus infections in Netherlands (Parenteral)
- 26 Apr 2017 Phase-II clinical trials in Influenza virus infections in Netherlands (Parenteral) (AIMM Therapeutics pipeline, April 2017)
- 14 Jan 2014 Anti-influenza monoclonal antibody - AIMM Therapeutics is available for licensing as of 14 Jan 2014. http://www.aimmtherapeutics.com/